Tuesday, March 13, 2012
Antigen Express' AE37 HER2 Peptide Vaccine Named to Shortlist for 5th Annual ViE Awards
Antigen Express' lead vaccine, the AE37 HER2/neu synthetic peptide vaccine, has has been named as a nominee for the BEST THERAPEUTIC VACCINE (approved or in development) according to the shortlist published today for the 5th Annual Vaccine Industry Excellence (ViE) Awards. The ViE awards, sponsored by Novartis Vaccines and Diagnostics, were created to recognize the accomplishments and contributions of companies and individuals in the vaccine industry over the previous 12 months.
The full list of nominees in the Best Therapeutic Vaccine category are:
•Advaxis: ADXS-HPV - HPV
•Antigen Express: AE37 - Breast cancer
•BioSante Pharmaceuticals: GVAX
•Galena Biopharma: NeuVax - Breast cancer
•ImmusanT: Nexvax2 - Celiac disease
•Inovio Pharmaceuticals: VGX-3100 - Cervical cancer
The ViE Award nominees are voted on by those in the global vaccine industry and also judged by a panel of representatives from pharma, biotech, academia, government, non-governmental organizations (NGOs), and public health. Winners are announced at the annual ViE Awards dinner and ceremony, taking place this year on April 11 during the World Vaccine Congress in Washington, D.C. Click on AE37 Vaccine to go to the ViE Awards link on the World Vaccine Congress' website.
Bring it home, Antigen Express!